Kiniksa Pharmaceuticals (KNSA)
(Real Time Quote from BATS)
$17.97 USD
+0.36 (2.04%)
Updated Apr 26, 2024 11:02 AM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KNSA 17.97 +0.36(2.04%)
Will KNSA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for KNSA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KNSA
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
KNSA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect?
Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates
Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great Choice
Other News for KNSA
Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Kiniksa price target raised by $5 at Evercore ISI, here's why
Buy Rating Affirmed for Kiniksa Pharmaceuticals Amid Strong Q1 Performance and Promising Drug Prospects
Kiniksa Pharmaceuticals, Ltd. 2024 Q1 - Results - Earnings Call Presentation
KNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024